Page 69 - rcv31n3.vp

Revista Uruguaya de Cardiología
Guía sobre doble antiagregación plaquetaria en pacientes con enfermedad coronaria
Volumen 31 | nº 3 | Diciembre 2016 Óscar Bazzino
32. Bittl JA, Baber U, Bradley SM, Wijeysundera and multivariable correlates of long-term mortality
DN, Halperin JL, Levine GN, et al. Duration of in patients treated with surgical or percutaneous re-
dual antiplatelet therapy: a systematic review for the vascularization in the synergy between percuta-
2016 ACC/AHA guideline focused update on duration neous coronaryintervention with taxus and cardiac
of dual antiplatelet therapy in patients with coronary surgery (SYNTAX) trial. Eur Heart J. 2012;33(24):
arterydisease: a report of the American College of 3105-13. doi: 10.1093/eurheartj/ehs367.
Cardiology/American Heart Association Task Force
41. Johnson WD, Kayser KL, Hartz AJ, Saedi SF.
on Practice Guidelines. J Am CollCardiol.
Aspirin use and survival after coronary bypass sur-
2016;68(10):1116-39.
gery. Am Heart J.1992;123(3):603-8.
doi: 10.1016/j.jacc.2016.03.512. Correction en: J Am
Coll Cardiol. 2016;68(10):1152-4 42. Chesebro JH, Clements IP, Fuster V, Elveback
LR, Smith HC, Bardsley WT, et al. A platelet-in-
33. Spencer FA, Prasad M, Vandvik PO, Chetan D,
hibitor-drug trial in coronary-artery bypass opera-
Zhou Q, Guyatt G. Longer versus shorter-duration
tions:benefit of perioperative dipyridamole and aspi-
dual-antiplatelet therapy after drugelutingstent pla-
rin therapy on early postoperative vein-graft pa-
cement: a systematic review and meta-analysis. Ann
tency. N Engl J Med.1982;307(2):73-8.
Intern Med. 2015;163(2):118-26.
doi: 10.7326/M15-0083. 43. Chesebro JH, Fuster V, Elveback LR, Clements
IP, Smith HC, Holmes DR Jr, et al. Effect of dipy-
34. Hermiller JB, Krucoff MW, Kereiakes DJ, Win-
ridamole and aspirin on late vein-graft patency after-
decker S, Steg PG, Yeh RW, et al. Benefits and
coronary bypass operations. N Engl J Med. 1984;
risks of extended dual antiplatelet therapy aftereve-
310(4):209-14.
rolimus-eluting stents. JACC Cardiovasc Interv.
2016;9(2):138-47. doi: 10.1016/j.jcin.2015.10.001. 44. Goldman S, Copeland J, Moritz T, Henderson
W, Zadina K, Ovitt T, et al. Improvement in early
35. Navarese EP, Kowalewski M, Kandzari D,
saphenous vein graft patency after coronary ar-
Lansky A, Górny B, Ko³towski L, et al. First-ge-
terybypass surgery with antiplatelet therapy: results
neration versus second-generation drug-eluting
of a Veterans Administration Cooperative Study.
stents incurrent clinical practice: updated evidence
Circulation1988;77(6):1324-32.
from a comprehensive meta-analysis of randomised
clinical trialscomprising 31 379 patients. Open 45. Ebrahimi R, Bakaeen FG, Uberoi A, Ardehali
Heart. 2014;1(1):e000064. A, Baltz JH, Hattler B, et al. Effect of clopidogrel
doi: 10.1136/openhrt-2014-000064. eCollection 2014. use post coronary artery bypass surgery on graft pa-
tency. Ann Thorac Surg. 2014;97(1):15-21.
36. Palmerini T, Kirtane AJ, Serruys PW, Smits doi: 10.1016/j.athoracsur.2013.08.058.
PC, Kedhi E, Kereiakes D, et al. Stent thrombosis
with everolimus-eluting stents: meta-analysis of- 46. Kulik A, Le May MR, Voisine P, Tardif JC, De-
comparative randomized controlled trials. Circ Car- larochelliere R, Naidoo S, et al. Aspirin plus clo-
diovasc Interv. 2012;5(3):357-64. pidogrel versus aspirin alone after coronary artery
doi: 10.1161/CIRCINTERVENTIONS.111.967083. bypassgrafting: the clopidogrel after surgery for co-
ronary artery disease (CASCADE) Trial. Circulation.
37. Räber L, Magro M, Stefanini GG, Kalesan B, 2010;122(25):2680-7.
van Domburg RT, Onuma Y, et al. Very late coro- doi: 10.1161/CIRCULATIONAHA.110.978007.
nary stent thrombosis of a newer-generation everoli-
muselutingstent compared with early-generation 47. Gao C, Ren C, Li D, Li L. Clopidogrel and aspirin
drug-eluting stents: a prospective cohort study. Cir- versus clopidogrel alone on graft patency after coro-
culation.2012;125(9):1110-21. nary arterybypass grafting. Ann Thorac Surg.
doi: 10.1161/CIRCULATIONAHA.111.058560. 2009;88(1):59-62.
doi: 10.1016/j.athoracsur.2009.04.024.
38. Sarno G, Lagerqvist B, Nilsson J, Frobert O,
48. Sun JCJ, Teoh KHT, Lamy A, Sheth T, Ellins
Hambraeus K, Varenhorst C, et al. Stent throm-
ML, Jung H, et al. Randomized trial of aspirin and
bosis in new-generation drug-eluting stents in pa-
clopidogrel versus aspirin alone for the prevention of
tients with STEMI undergoing primary PCI: a report
coronary artery bypass graft occlusion: the preopera-
from SCAAR. J Am Coll Cardiol. 2014;64(1):16-24.
tive aspirin and postoperative antiplatelets in coro-
doi: 10.1016/j.jacc.2014.04.022.
nary artery bypass grafting study. Am Heart J.
39. Urban P, Meredith IT, Abizaid A, Pocock SJ, 2010;160(6):1178-84. doi: 10.1016/j.ahj.2010.07.035.
Carrié D, Naber C, et al. Polymer-free drug-coated
49. Gao G, Zheng Z, Pi Y, Lu B, Lu J, Hu S. Aspirin
coronary stents in patients at high bleeding risk. N
plus clopidogrel therapy increases early venous graft
Engl J Med. 2015;373(21):2038-47.
patency after coronary artery bypass surgery a sin-
doi: 10.1056/NEJMoa1503943.
gle-center, randomized, controlled trial. J Am Coll
40. Farooq V, Serruys PW, Bourantas C, Vranckx Cardiol. 2010;56(20):1639-43.
P, Diletti R, Garcia Garcia HM, et al. Incidence doi: 10.1016/j.jacc.2010.03.104.
425